Protalix BioTherapeutics, Inc. (PLX)
USD 1.71
(-1.72%)
USD 1.71
(-1.72%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 65.49 Million USD | 37.48% |
| 2022 | 47.63 Million USD | 24.22% |
| 2021 | 38.35 Million USD | -39.03% |
| 2020 | 62.89 Million USD | 15.0% |
| 2019 | 54.69 Million USD | 59.73% |
| 2018 | 34.24 Million USD | 77.94% |
| 2017 | 19.24 Million USD | 109.17% |
| 2016 | 9.19 Million USD | 110.79% |
| 2015 | 4.36 Million USD | -71.21% |
| 2014 | 15.16 Million USD | 31.68% |
| 2013 | 11.51 Million USD | -66.56% |
| 2012 | 34.42 Million USD | 310.49% |
| 2011 | 8.38 Million USD | 26.26% |
| 2010 | 6.64 Million USD | 1611.86% |
| 2009 | 388 Thousand USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 150 Thousand USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | -100.0% |
| 2000 | 1.00 USD | -100.0% |
| 1999 | 3.55 Million USD | -55.76% |
| 1998 | 8.03 Million USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 3.74 Million USD | -64.26% |
| 2024 Q2 | 13.47 Million USD | 259.5% |
| 2023 Q1 | 9.58 Million USD | 11.27% |
| 2023 FY | 65.49 Million USD | 37.48% |
| 2023 Q3 | 10.34 Million USD | -70.51% |
| 2023 Q2 | 35.07 Million USD | 265.82% |
| 2023 Q4 | 10.48 Million USD | 1.36% |
| 2022 Q1 | 16.08 Million USD | 88.15% |
| 2022 Q2 | 8.75 Million USD | -45.58% |
| 2022 Q3 | 14.18 Million USD | 62.04% |
| 2022 FY | 47.63 Million USD | 24.22% |
| 2022 Q4 | 8.61 Million USD | -39.24% |
| 2021 Q2 | 6.42 Million USD | -43.22% |
| 2021 Q1 | 11.32 Million USD | -41.93% |
| 2021 Q3 | 12.05 Million USD | 87.55% |
| 2021 FY | 38.35 Million USD | -39.03% |
| 2021 Q4 | 8.54 Million USD | -29.08% |
| 2020 Q4 | 19.49 Million USD | 80.68% |
| 2020 Q1 | 21.64 Million USD | 21.89% |
| 2020 Q2 | 10.96 Million USD | -49.33% |
| 2020 Q3 | 10.79 Million USD | -1.61% |
| 2020 FY | 62.89 Million USD | 15.0% |
| 2019 Q3 | 14.24 Million USD | 16.34% |
| 2019 FY | 54.69 Million USD | 59.73% |
| 2019 Q1 | 10.43 Million USD | -61.36% |
| 2019 Q2 | 12.24 Million USD | 17.32% |
| 2019 Q4 | 17.75 Million USD | 24.64% |
| 2018 Q4 | 27.01 Million USD | 3975.11% |
| 2018 Q3 | 663 Thousand USD | -66.95% |
| 2018 Q1 | 4.55 Million USD | 84.41% |
| 2018 FY | 34.24 Million USD | 77.94% |
| 2018 Q2 | 2 Million USD | -55.94% |
| 2017 FY | 19.24 Million USD | 109.17% |
| 2017 Q2 | 6.35 Million USD | 120.08% |
| 2017 Q4 | 2.46 Million USD | -67.19% |
| 2017 Q3 | 7.52 Million USD | 18.37% |
| 2017 Q1 | 2.88 Million USD | 38.83% |
| 2016 Q1 | 679 Thousand USD | 106.07% |
| 2016 Q3 | 4.67 Million USD | 163.99% |
| 2016 Q2 | 1.76 Million USD | 160.53% |
| 2016 FY | 9.19 Million USD | 110.79% |
| 2016 Q4 | 2.08 Million USD | -55.44% |
| 2015 Q2 | 4.61 Million USD | -9.44% |
| 2015 FY | 4.36 Million USD | -71.21% |
| 2015 Q4 | -11.19 Million USD | -291.5% |
| 2015 Q3 | 5.84 Million USD | 26.65% |
| 2015 Q1 | 5.09 Million USD | 268.28% |
| 2014 FY | 15.16 Million USD | 31.68% |
| 2014 Q4 | 1.38 Million USD | -62.67% |
| 2014 Q1 | 7.38 Million USD | 558.02% |
| 2014 Q3 | 3.7 Million USD | 38.01% |
| 2014 Q2 | 2.68 Million USD | -63.62% |
| 2013 Q1 | 3.96 Million USD | 8166.67% |
| 2013 Q3 | 3.35 Million USD | 9.63% |
| 2013 FY | 11.51 Million USD | -66.56% |
| 2013 Q4 | 1.12 Million USD | -66.6% |
| 2013 Q2 | 3.06 Million USD | -22.78% |
| 2012 FY | 34.42 Million USD | 310.49% |
| 2012 Q4 | 48 Thousand USD | -99.11% |
| 2012 Q3 | 5.39 Million USD | -79.36% |
| 2012 Q1 | 3.72 Million USD | 57.83% |
| 2012 Q2 | 26.11 Million USD | 600.46% |
| 2011 Q3 | 1.13 Million USD | 48.17% |
| 2011 Q2 | 764 Thousand USD | -87.27% |
| 2011 Q1 | 6 Million USD | 410.2% |
| 2011 Q4 | 2.36 Million USD | 108.66% |
| 2011 FY | 8.38 Million USD | 26.26% |
| 2010 Q2 | 1.14 Million USD | 0.0% |
| 2010 Q3 | 3.18 Million USD | 179.05% |
| 2010 FY | 6.64 Million USD | 1611.86% |
| 2010 Q4 | 1.17 Million USD | -63.07% |
| 2010 Q1 | 1.14 Million USD | 194.07% |
| 2009 Q4 | 388 Thousand USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | 388 Thousand USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 FY | - USD | -100.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | -100.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | 150 Thousand USD | 0.0% |
| 2006 Q4 | 150 Thousand USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 Q3 | - USD | -100.0% |
| 2001 FY | - USD | -100.0% |
| 2001 Q2 | 1.00 USD | 0.0% |
| 2001 Q1 | 1.00 USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2000 Q3 | 1.00 USD | 0.0% |
| 2000 FY | 1.00 USD | -100.0% |
| 2000 Q1 | 1.00 USD | -100.0% |
| 2000 Q4 | - USD | -100.0% |
| 2000 Q2 | 1.00 USD | 0.0% |
| 1999 Q2 | 1.18 Million USD | -45.36% |
| 1999 Q1 | 2.16 Million USD | -23.31% |
| 1999 FY | 3.55 Million USD | -55.76% |
| 1999 Q4 | 43.38 Thousand USD | -73.98% |
| 1999 Q3 | 166.75 Thousand USD | -85.89% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | 2.32 Million USD | 0.0% |
| 1998 Q3 | 2.9 Million USD | 25.0% |
| 1998 Q4 | 2.82 Million USD | -2.76% |
| 1998 FY | 8.03 Million USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 202 Thousand USD | -32322.772% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Armata Pharmaceuticals, Inc. | 4.52 Million USD | -1346.103% |
| Actinium Pharmaceuticals, Inc. | 81 Thousand USD | -80756.79% |
| Azitra, Inc. | 686 Thousand USD | -9447.23% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | -8714.805% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | - USD | -Infinity% |
| CEL-SCI Corporation | - USD | -Infinity% |
| iBio, Inc. | 225 Thousand USD | -29008.444% |
| Lineage Cell Therapeutics, Inc. | 8.94 Million USD | -632.186% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 1.09 Million USD | -5875.73% |
| Navidea Biopharmaceuticals, Inc. | 65.65 Thousand USD | -99659.337% |
| NovaBay Pharmaceuticals, Inc. | 14.72 Million USD | -344.751% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 37.65 Thousand USD | -173840.987% |
| BiomX Inc. | -357 Thousand USD | 18445.658% |
| BiomX Inc. | -357 Thousand USD | 18445.658% |
| Palatin Technologies, Inc. | 4.49 Million USD | -1358.634% |
| Scorpius Holdings, Inc. | 6.99 Million USD | -836.319% |